Lyndra Therapeutics and Gilead Sciences have entered a partnership collaboration to develop and market ultra-long-acting oral HIV therapies. Gilead will pick up exclusive rights to Lyndra’s long-acting drug platform.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,